Abstract:Many clinical studies have shown that induction chemotherapy followed by concurrent chemoradiotherapy improved the survival of locally advanced nasopharyngeal carcinoma (NPC). However, it is still unknown that which induction chemotherapy regimen is the optimal choice. This study focused on the comparison of efficacy and toxicities between induction chemotherapy regimen TPF and GP in locally advanced NPC. Between January 2008 and July 2015, patients with locally advanced NPC (clinical stage III-IVb) were retrospectively analyzed. Inclusion criteria were as follows: (1) pathologically confirmed NPC; (2) clinical stage III-IVb according to the 7th edition of the American Joint Committee on Cancer (AJCC) stage criteria; (3) receiving either TPF regimen plus CCRT or GP regimen plus CCRT; (4) radiotherapy was performed using intensity modulated radiation therapy (IMRT). Exclusion criteria were as follows: (1) patients receiving adjuvant chemotherapy; (2) patients with other malignant diseases. The primary endpoint was overall survival (OS). The Secondary endpoints included progression-free survival (PFS), distant metastasis-free survival (DMFS) and locoregional recurrence-free survival (LRFS). The Kaplan-Meier survival curves and log-rank test were used to evaluate the OS, PFS, LRFS, and DMFS of the two groups. Univariate and multivariate analyses were applied to identify the independent prognostic factors. Chi-square test was performed to compare the toxic effects between the two groups. A total of 80 patients treated with TPF regimen plus CCRT and 80 with GP regimen plus CCRT were eligible for this study. After a median follow-up of 47 months (range 8–97months), no differences were observed between the two groups in terms of 3-year OS (86.1% vs. 94.8%, p = 0.123), PFS (81.1% vs. 90.8%, p = 0.224), DMFS (82.3% vs. 94.1%, p = 0.087), or LRFS (93.6% vs.96.1%, p = 0.794). The results of the multivariate Cox proportional hazard analysis showed that the treatment group was not an independent prognostic factor for OS (HR 2.341; 95% CI 0.878–6.241; p = 0.089), PFS (HR 1.814; 95% CI 0.815–4.036; p=0.145), DMFS (HR 2.343; 95%CI 0.942–5.830; p = 0.067), or LRFS (HR 1.243; 95% CI 0.377–4.103; p = 0.721). Clinical stage was an independent prognostic factor affecting OS (HR 0.198; 95 %CI 0.040–0.975; p = 0.046) and PFS (HR 0.224; 95 %CI 0.062–0.810; p = 0.023).There was significant difference in III-IV hepatic toxicity between the two groups (0 vs. 18.6%, p=0.000). No significant differences were observed in bone marrow suppression and kidney dysfunction between the two arms. GP induction chemotherapy plus CCRT achieved similar survival outcomes to those with TPF induction chemotherapy for locally advanced NPC. However, GP regimen increased grade 3–4 hepatic dysfunction compared with TPF induction chemotherapy. More prospective clinical trials are needed to determine the most effective induction chemotherapy regimen for locally advanced NPC.

Optimizing the Induction Chemotherapy Regimen for Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Big-Data Intelligence Platform-Based Analysis

Cisplatin and Fluorouracil Induction Chemotherapy With or Without Docetaxel in Locoregionally Advanced Nasopharyngeal Carcinoma.

Efficacy and Toxicity of Three Induction Chemotherapy Regimens in Locoregionally Advanced Nasopharyngeal Carcinoma: Outcomes of 10-Year Follow-Up

Therapeutic Evaluation of Induction Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma With Low-risk <i>N</i> Stage A Multicenter Retrospective Study From Nonendemic Region of China

Induction Chemotherapy Improved Long-term Outcomes of Patients with Locoregionally Advanced Nasopharyngeal Carcinoma: A Propensity Matched Analysis of 5-year Survival Outcomes in the Era of Intensity-modulated Radiotherapy.

Optimal induction chemotherapeutic regimen followed by concurrent chemotherapy plus intensity-modulated radiotherapy as first-line therapy for locoregionally advanced nasopharyngeal carcinoma

The Most Efficacious Induction Chemotherapy Regimen for Locoregionally Advanced Nasopharyngeal Carcinoma: A Network Meta-Analysis

Retrospective Analysis of Induction Chemotherapy plus Concurrent Chemoradiotherapy under Intensity-Modulated Radiotherapy Mode for Locally Advanced Nasopharyngeal Carcinoma

WITHDRAWN: Interim Analysis of a Prospective Randomized Non-Inferiority Trial of Cisplatin and Fluorouracil Induction Chemotherapy with or Without Docetaxel in Nasopharyngeal Carcinoma

Therapeutic Evaluation of Induction Chemotherapy for Locoregionally Advanced Nasopharyngeal Carcinoma With Low-risk N Stage

Induction Chemotherapy Followed by Intensity-Modulated Radiotherapy Versus Concurrent Chemoradiotherapy in Nasopharyngeal Carcinoma: A Retrospective Analysis

Nomogram-aided individual induction chemotherapy regimen selection in advanced nasopharyngeal carcinoma

Induction chemotherapy for the treatment of non-endemic locally advanced nasopharyngeal carcinoma

Assessment of Induction Chemotherapy Regimen TPF Versus GP Followed by Concurrent Chemoradiotherapy in Locally Advanced Nasopharyngeal Carcinoma: A Retrospective Cohort Study

The efficacy of induction chemotherapy or adjuvant chemotherapy added to concurrent chemoradiotherapy in T3-4N0-1M0 nasopharyngeal carcinoma: a propensity score-matched analysis

Which induction chemotherapy regimen followed by cisplatin-based concurrent chemoradiotherapy is the best choice among PF, TP and TPF for locoregionally advanced nasopharyngeal carcinoma?

Induction chemotherapy followed by concurrent chemoradiotherapy vs. concurrent chemoradiotherapy for locoregionally advanced nasopharyngeal carcinoma: a retrospective cohort study

Assessment of Response to Different Induction Chemotherapy Regimens in Locally Advanced Nasopharyngeal Carcinoma

Propensity-matched analysis of three different chemotherapy sequences in patients with locoregionally advanced nasopharyngeal carcinoma treated using intensity-modulated radiotherapy

Impact of Chemotherapy Compliance on the Therapeutic Efficacy of Patients with Locally Advanced Nasopharyngeal Carcinoma

Survival benefit of induction chemotherapy for locally advanced nasopharyngeal carcinoma: prognosis based on a new risk estimation model